Using an immune “hot” mouse ovarian cancer model, the authors discovered that the inhibition of HH signaling with the SMOi IPI-926 reverses CA-MSC–driven tumor immune exclusion and restores response to anti-PDL1 therapy. Here, CD274 is linked to ovarian carcinoma.